<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13260">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884207</url>
  </required_header>
  <id_info>
    <org_study_id>MCOT_03_05</org_study_id>
    <nct_id>NCT01884207</nct_id>
  </id_info>
  <brief_title>Multiparametric Characterization of Orbital Tumors by MRI</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study on patients with orbital tumors of unknown origin. Aim of the study is to
      differentiate benign from malignant tumors upon MR imaging. Magnetic resonance imaging of
      the orbit will be performed including standard morphological sequences and advanced sequence
      techniques. These advanced sequence techniques may allow to differentiate benign from
      malignant tumors based on their cellularity and vascularity (diffusion and perfusion
      imaging). These MRI data will be analysed and the level of diffusion and perfusion will be
      measured and compared to the histological findings. Cut-off values of diffusion and
      perfusion will be calculated that allow to separate benign from malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>multiparametric characterization of orbital tumors by MRI</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The level of diffusion and perfusion (multiparametric characterization) of the orbital tumors will be measured and the outcome measure is the ability of diffusion and perfusion imaging to predict malignancy. These parameters will be compared to histopathology in terms of separating benign vs. malignant tumors.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Orbital Tumors</condition>
  <arm_group>
    <arm_group_label>orbital tumors</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>orbital tumors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with orbital tumors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-diagnosed orbital tumors

        Exclusion Criteria:

          -  any metal implants, non-MRI compatible

          -  age below 18

          -  pregnancy

          -  recent surgery

          -  recent severe medical diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Asbach, PD Dr.</last_name>
    <phone>+4930 450 527 723</phone>
    <email>patrick.asbach@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katharina Erb-Eigner, Dr.</last_name>
    <phone>+4930 8445 3041</phone>
    <email>katharina.erb@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite University</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Erb-Eigner, Dr.</last_name>
      <phone>+4930 8445 3041</phone>
      <email>katharina.erb@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 19, 2013</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Sa-Ra Ro</investigator_full_name>
    <investigator_title>doctoral candidate</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Orbital Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
